Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

NIH awards $10.5 million grant for OCD treatment research

A new research center exploring the science underlying a potential new treatment for obsessive-compulsive disorder has been established at the University of Rochester Medical Center, thanks to a $10.5 million award from the National Institute of Mental Health.

1 Oct 2009

UCF research team develops miniature diagnostic tool kit for dementia

With the risk of developing dementia growing at an alarming pace, a University of Central Florida research team is working with the Boston University School of Medicine to develop a miniature diagnostic toolkit in the hopes of stimulating earlier detection and treatment.

1 Oct 2009

Streptococcal infection does not cause OCD or Tourette syndrome, says study

New research shows that streptococcal infection does not appear to cause or trigger Tourette syndrome or obsessive-compulsive disorder (OCD). The research is published in the September 30, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology.

1 Oct 2009

FDA approves Mylan Pharmaceuticals' Carbidopa and Levodopa tablets

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Carbidopa and Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg.

30 Sep 2009

Life Technologies Foundation awards grants for advancements in science

The Life Technologies Foundation, a non-profit arm of Life Technologies Corporation dedicated to advancing science education and scientific discovery, has awarded approximately $1.7 million in new grants that include the creation of an online biology textbook, and building a museum exhibit about the human cell.

30 Sep 2009

Stem Cell Therapy International merges with Histostem

Stem Cell Therapy International, Inc. is proud to announce the execution of the Reorganization and Stock Purchase Agreement ("the Agreement") with Histostem Co., Ltd., a Korean company ("Histostem" and together with SCII, "the parties").

25 Sep 2009

Researchers study about abnormal gene functioning in mitochondria

Researchers are delving into abnormal gene function in mitochondria, structures within cells that power our lives. Mitochondria are the place where energy is generated from the most basic molecules of food. Because this function is essential to life, defects in mitochondria may affect a wide range of organ systems in humans and animals.

25 Sep 2009

Chronic sleep deprivation linked to early incidence of Alzheimer's brain plaques

Chronic sleep deprivation in a mouse model of Alzheimer's disease makes Alzheimer's brain plaques appear earlier and more often, researchers at Washington University School of Medicine in St. Louis report online this week in Science Express.

25 Sep 2009

Tooth cell banking for the treatment of future diseases

Pioneered by BioEDEN, tooth cell banking is a safe, natural and wholly non-invasive method of collecting and preserving precious stem cells which could hold the key to children's health.

25 Sep 2009

Study on mitochondria function

For such crucial biological actors, much remains unknown about exactly how mitochondria function. A new study, published Aug. 12 in the online journal PLoS One, sheds light on mitochondrial biology. Using genetic engineering, researchers interrupted the activity of individual genes directly involved in the production of energy within mitochondria. "If we knock down the function of specific system components, what happens?" said study leader Marni J. Falk, M.D., who directs the Mitochondrial-Genetics Disease Clinic at The Children's Hospital of Philadelphia. "Our ultimate goal is to translate the knowledge into targeted therapies, that is, effective ways to intervene. But first we need to understand the underlying disease mechanisms."

25 Sep 2009

Amorfix Life Sciences to present Amorfix's EP-vCJD blood screening test for vCJD at WFH Global Forum

Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, announced today that its Chief Executive Officer, Dr. George Adams, will present Amorfix's EP-vCJD(TM) blood screening test for variant Creutzfeldt-Jakob Disease ("vCJD") at the Sixth World Federation of Hemophilia ("WFH") Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders in Montreal, Quebec at 11:00 am ET on Friday, September 25, 2009.

24 Sep 2009

NIH awards three UNC Scientists for high risk and innovative research

Three scientists from the University of North Carolina at Chapel Hill School of Medicine and the UNC Lineberger Comprehensive Cancer Center have received prestigious awards from the National Institutes of Health (NIH) aimed at encouraging "high risk" and innovative research.

24 Sep 2009

Rasagiline slows the rate of Parkinson's disease progression

Following one of the largest studies ever conducted in Parkinson's disease (PD), researchers at Mount Sinai School of Medicine report today in The New England Journal of Medicine that rasagiline, a drug currently used to treat the symptoms of PD, may also slow the rate of disease progression.

24 Sep 2009

ADAGIO clinical trial results demonstrating AZILECT's efficacy published

Results from the ADAGIO trial, published online today in The New England Journal of Medicine, demonstrated that Parkinson’s disease patients receiving AZILECT (rasagiline) 1mg/day at the start of the study (early-start group) experienced superior benefit over 18 months compared with those who started the exact same treatment nine months later (delayed-start group).

24 Sep 2009

FDA accepts Sangamo's IND for repeat-dosing in Phase 1 clinical trial of SB-728-T ZFN-based therapeutic

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.

23 Sep 2009

Researching the causes of Alzheimer's disease

The standard explanation for what causes Alzheimer's is known as the amyloid hypothesis, which posits that the disease results from of an accumulation of the peptide amyloid beta, the toxic protein fragments that deposit in the brain and become the sticky plaques that have defined Alzheimer's for more than 100 years.

23 Sep 2009

Declining performance of muscles linked to harmful byproducts of air we breathe

If you think the air outside is polluted, a new research report in the September 2009 issue of the journal Genetics (http://www.genetics.org) might make you to think twice about the air inside our bodies too. That's because researchers show how about 3 percent of the air we breathe gets converted into harmful superoxides, which ultimately harm our muscles.

23 Sep 2009

UAB's researchers find early indicators for Alzheimer's disease

Inability to handle financial transactions or manage money may be an early indicator that a person with mild memory problems soon is likely to develop Alzheimer's disease, according to new research from the University of Alabama at Birmingham (UAB) Alzheimer's Disease Center, part of the Department of Neurology.

22 Sep 2009

Amorfix announces 100% specificity upon testing 10,000 blood donations for vCJD

Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, today announced it has achieved 100% specificity (no reproducible false positive results) upon testing 10,000 blood donations for variant Creutzfeldt-Jakob Disease ("vCJD"). with the EP-vCJD(TM) Blood Screening Assay at l'Etablissement Français du Sang de Pyrénées Méditerrannée ("EFS-PM") in Montpellier, France.

22 Sep 2009

Poor money management: A sign of developing Alzheimer's disease

New research finds poor money management skills may indicate that a person with mild memory problems will soon develop Alzheimer's disease. The study is published in the September 22, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology.

22 Sep 2009